Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared a post on LinkedIn:
“Amivantanab monotherapy (23 pts) and with Folfox/folferi (7 pts in right-sided Metastatic CRC, With prior 2 to 3 lines of therapy and prior anti-EGFR therapy allowed.
It shows good DCR (78%) with median pfs of 3.7 months and Median DOR 7.4 months for monotherapy.
Intresting results. Will like to see toxicity data in details.
As in NSCLC, will sub-cut amivantanab be better in CRC also?”
More posts featuring Amol Akhade.
